ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-OR039

Two-Year Change in Galectin 3 and MMP-2 and Risk of ESRD: The Chronic Renal Insufficiency Cohort (CRIC) Study

Session Information

  • Biomarkers in CKD
    November 09, 2019 | Location: 152, Walter E. Washington Convention Center
    Abstract Time: 04:42 PM - 04:54 PM

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Anderson, Amanda Hyre, Tulane University, New Orleans, Louisiana, United States
  • Orlandi, Paula Ferreira, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Yang, Wei, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Baudier, Robin Leigh, Tulane University, New Orleans, Louisiana, United States
  • Susztak, Katalin, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Srivastava, Anand, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Ricardo, Ana C., University of Illinois at Chicago, Chicago, Illinois, United States
  • Dobre, Mirela A., Case Western Reserve University, Cleveland, Ohio, United States
  • Deo, Rajat, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Chen, Jing, Tulane School of Medicine, New Orleans, Louisiana, United States
  • He, Jiang, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, United States
  • Shafi, Tariq, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Chen, Hsiang-Yu, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Xie, Dawei, University of Pennsylvania School of Medicine Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania, United States
  • Bansal, Nisha, Kidney Research Institute, Seattle, Washington, United States
  • Feldman, Harold I., University of Pennsylvania, Philadelphia, Pennsylvania, United States
Background

Galectin-3 and matrix metalloproteinase-2 (MMP-2) have both been associated with kidney fibrosis, however, the relationship of these markers with chronic kidney disease (CKD) progression remains unclear.

Methods

A case-cohort study including a randomly selected sample of 1300 CRIC participants was conducted to characterize the association of two-year change in plasma galectin-3 and MMP-2 with subsequent development of end-stage renal disease (ESRD; N=542). Weighted Cox proportional hazards regression models used data from up to 8 years of follow-up, adjusted for sociodemographic, clinical and biochemical factors including eGFR and proteinuria in addition to galectin-3 or MMP-2 values from baseline.

Results

Two-year change in galectin-3 ranged from -51 to + 56 ng/mL with an overall mean change of 4.3 ng/mL, while change in MMP-2 ranged from -455 to +654 ng/mL (mean change: 25.4 ng/mL). Restricted cubic splines demonstrate non-linear associations for both markers (Figure). Increases in galectin-3 over two years did not appear to increase ESRD risk, but decreases may trend toward reduced risk of ESRD. The hazard ratio for MMP-2 reductions of 400 ng/mL was 0.2 (95% CI: 0.1-0.5).

Conclusion

Decreases in MMP-2 over two years are strongly and independently associated with marked reduction in the risk for ESRD among patients with established CKD. This pathway should be studied further to investigate possible interventions to reduce CKD progression risk.

Funding

  • NIDDK Support